PRO MEDICUS LIMITED — Director's Dealing 2026

Feb 23, 2026

Appendix 3Y Change of Director’s Interest Notice

Listing Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Pro Medicus Limited ABN 25 006 194 752

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Terence KEMPEN
Date of last notice	30 December 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [408 x 309] intentionally omitted <==

----- Start of picture text ----- Direct or indirect interest DirectNature of indirect interest Ordinary fully paid shares in Pro Medicus(including registered holder) Limited held by EMK Investments Pty Ltd ofNote: Provide details of the circumstances giving rise to the relevant interest. which the Director is a director and beneficialownerDate of change 23 February 2026No. of securities held prior to change 629,682 ordinary shares consisting of: - 200,000 ordinary shares held underPeter Terence KEMPEN 428,082 ordinary shares held underElaine Kempen Superannuation Fundof which the Director is a Trustee andMember 1,600 ordinary shares held underEMK Investments Pty Ltd of whichthe Director is a director andbeneficial ownerClass Ordinary shares----- End of picture text -----

• See chapter 19 for defined terms.

11/3/2002

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

==> picture [409 x 388] intentionally omitted <==

----- Start of picture text ----- Number acquired 400Number disposed NilValue/Consideration $116.43 per shareNote: If consideration is non-cash, provide details and estimated valuationNo. of securities held after change 630,082 ordinary shares consisting of: - 200,000 ordinary shares held underPeter Terence KEMPEN 428,082 ordinary shares held underElaine Kempen Superannuation Fundof which the Director is a Trustee andMember 2,000 ordinary shares held underEMK Investments Pty Ltd of whichthe Director is a Director andbeneficial ownerNature of change On market purchaseExample: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back----- End of picture text -----

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relationto which the interest has changed	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No
If so, was prior-written clearance provided to allow thetrade to proceed during this period?	N/A
If prior written clearance was provided, on what date wasthis provided?	N/A

For and on behalf of Pro Medicus Limited

==> picture [132 x 60] intentionally omitted <==

Danny English Company Secretary 24 February 2026

• See chapter 19 for defined terms.

11/3/2002

Appendix 3Y Page 3